Articles

This trend has important implications for Social Security’s full retirement age

New data show strong relationship between earnings and life expectancy

Consumer confidence sinks to 8-month low on worries about inflation and Trump tariffs

A post-election high in consumer confidence after the election of Donald Trump has petered out, as the public digests major upheavals in U.S. economic policies by the new White House.

Fed’s Logan backs shortening maturity of central bank’s balance sheet

Dallas Fed President Lorie Logan on Tuesday backed a plan to change the composition of the Fed’s secondary-market purchases of Treasury securities so that the central bank’s holdings match the government’s maturity profile.

This momentum-stock fund can lower your risk. It has outperformed the S&P 500.

It might surprise you that a strategy focused on the best recent performers can limit downside risk and ride high during bull markets.

Tesla sales slid by nearly 50% across Europe at the start of 2025

A drop in new registrations for Tesla came even as sales of battery-electric vehicles rose an overall 34% in the region, with Volkswagen and SAIC Motor increasing their market share.

Looking forward to the great wealth transfer? Expect an $84 trillion mess instead.

Without proper estate planning, a lot of that money could end up going toward legal fees and taxes instead of to heirs.

Krispy Kreme stock heads for record low as earnings set for further disappointment

Krispy Kreme reported fourth-quarter results before market open.

Eli Lilly cuts price of weight-loss drug Zepbound for self-paying patients

The drug company is calling on insurers and federal programs to include coverage of obesity as a chronic disease.

Planet Fitness shares stumble as outlook points to slower earnings growth

Planet Fitness’ stock falls as the full-year earnings growth outlook disappoints.

There are dot-com echoes beyond tech. This Costco shareholder explains why returns will be paltry at best.

A fund manager says there are parallels between now and the 1998-to-2000 period, and not just in the megacap tech stocks

Novo Nordisk’s stock is rallying as Hims & Hers’ stock falters. An Ozempic alternative won’t be available for long.

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer.

No ‘golden age’ is coming. Trump’s tariffs will hit Americans with higher interest rates and more inflation.

Protectionism won’t make us rich — especially if tariffs launch a trade war.
1 93 94 95 96 97 2,020